Abstract
The incidence of pediatric cancer is relatively rare, particularly when compared to rates in the adult oncology. Despite the relative low numbers, death due to cancer remains the primary cause of death due to disease in the pediatric population. Pediatric cancer cure rates have markedly improved in the past several decades with well over 70% of pediatric cancer patients achieving cure. However, there remains a subset of patients who have a dismal prognosis either due to tumor type or stage at presentation or relapse. As a result, there is a great need for novel therapeutics and innovative approaches in this population. The development of new therapies is being extensively explored in the adult oncology population; however, the advancement of such drugs in pediatrics has been much slower.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
